ALEX Ups The Ante For Alecensa In ALK+ NSCLC
Executive Summary
Roche's Alecensa has bested Pfizer's Xalkori in the Phase III head-to-head ALEX study in first-line non-small-cell lung cancer, making a strong case for it to be the new gold standard therapy in ALK-positive patients, in favor of Novartis's Zykadia.
You may also be interested in...
Keeping Track: US FDA Approvals Of Mavyret, Idhifa, Vyxeos Headline Week Of Breakthroughs, Hematology And Hematology BTDs
The latest drug development news and highlights from our FDA Performance Tracker.
Keeping Track: US FDA Approvals Of Mavyret, Idhifa, Vyxeos Headline Week Of Breakthroughs, Hematology And Hematology BTDs
The latest drug development news and highlights from our FDA Performance Tracker.
It's Not All About IO: Seven Drugs To Watch At ASCO
Biomedtracker's review of ASCO abstracts revealed several drugs to watch outside of the immuno-oncology space at the annual cancer conference in Chicago, including market-expanding data for Roche's Perjeta and J&J's Zytiga, and Phase III data for AstraZeneca's PARP inhibitor Lynparza in breast cancer.